Peter Rossing (Steno Diabetes Center Copenhagen, University of Copenhagen)

2012 Professor in Endocrinology

2004 Copenhagen University Hospitals, Specialist: internal medicine-endocrinology

1998 University of Copenhagen: Doctoral thesis in Medicine

1991 University of Copenhagen Denmark, MD,

I have in cross-sectional studies investigated key features of the pathophysiology of diabetic complications with focus on the diabetic kidney at different stages and cardiovascular complications. The research group has continued the search for useful prognostic and predictive new biomarkers of risk for loss of renal function, including markers of endothelial dysfunction, tubular damage markers, markers of inflammation, metabolomic or proteomic based markers in urine and plasma. This was done both in relation to renal and cardiovascular outcome. I have been involved in a number of cohort studies in both type 1 and type 2 diabetes patients trying to identify risk factors/markers as well as new diagnostic strategies for cardiovascular disease. This includes multiple cohorts with +1000 people with type 1 or type 2 diabetes.

I have been involved in several intervention studies in patients with overt diabetic nephropathy aiming at improving the prognosis. This has either been in small local investigator initiated studies or as partner or coordinator in multicentre studies, as well as member of steering committees. I have been involved in several EU projects, including as work package leader in SYSKID with 25 partners in total, and more recently coordinator of the FP7 programme PRIORITY with 15 partners and a budget of 8 Mio Euro aiming at showing the benefit of the urinary proteome based risk marker CKD 273 and intervention in high risk individuals with aldosterone blockade (Lancet Diabetes &Endo 2020). Coordinator of the Challenge project PROTON (60 mio DKK) on personalised medicine for diabetic kidney disease, and PRIMETIME (10 mio DKK) using biopsies for treatment of kidney disease.

Has been PI for multiple cohort collections of people with diabetes, type 1 and type 2, with focus on identification of genetic and non-genetic biomarkers and imaging modalities to identify people at risk for kidney, cardiovascular and neuropathy complications.

Has been international/national investigator or partner in intervention studies or cohort studies. Member of the steering and writing group for PERL (NEJM 2020) the phase 3 renal outcome studies Fidelio (NEJM 2020)/Figaro (ESC 2021) DAPA CKD (NEJM 2020) FLOW (NEJM 2024) CONFIDENCE (NEJM 2026) FINEONE and MOSAIQUE on treatment of diabetic kidney disease.

1) Tofte N, Lindhardt M, ……, Rossing P; PRIORITY investigators. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. Lancet Diabetes Endocrinol. 2020 Apr;8(4):301-312.

2) de Boer IH, Caramori ML, .. Rossing P. Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment. Kidney Int. 2020 Oct;98(4):839-848

3) Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, .. Filippatos G; FIDELIO-DKD Investigators. N Engl J Med. 2020 Dec 3;383(23):2219-2229

4) Inker LA, Eneanya ND, .. Rossing P, .., Levey AS; Chronic Kidney Disease Epidemiology Collaboration. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021 Nov 4;385(19):1737-1749. doi: 10.1056/NEJMoa2102953. Epub 2021 Sep 23.

5) Dapagliflozin in Patients with Chronic Kidney Disease. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC; DAPA-CKD Trial Committees and Investigators. N Engl J Med. 2020 Oct 8;383(15):1436-1446.